Argos Wealth Advisors’s AstraZeneca AZN Stock Holding History

Argos Wealth Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$368K	Buy	1,939 +72	+4%	+$13.5K	0.1%	127
2026 Q1	$368K	Hold	1,867	–	–	0.11%	115
2025 Q4	$343K	Buy	+1,867	New	+$327K	0.09%	121

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Argos Wealth Advisors's AZN Position: Q2 2026 in Review

Argos Wealth Advisors increased its AstraZeneca (AZN) stake by 3.9% in Q2 2026, buying an estimated $13.5K and bringing the position to 1,939 shares worth $368K. The position accounts for 0.1% of the portfolio, ranked #127.

Argos Wealth Advisors first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $368K in Q1 2026. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Argos Wealth Advisors held 1,939 shares of AstraZeneca worth $368K as of Q2 2026.
Argos Wealth Advisors bought 72 AstraZeneca shares in Q2 2026, an estimated $13.5K.
AstraZeneca made up 0.1% of Argos Wealth Advisors's portfolio in Q2 2026, its #127 holding.
Argos Wealth Advisors first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
Argos Wealth Advisors's AstraZeneca position peaked at $368K in Q1 2026.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Argos Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.